Solana Company Class A Common Stock (DE) (HSDT)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style analyst, asking whether the business earns dependable profits and whether the price offers protection. Solana Company fails the first test. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $2.5 million while net income was -$30.3 million. The prior quarter, ended 2026-03-31, lost $99.8 million on $3.6 million of revenue. In FY2025, ended 2025-12-31, revenue was only $548,000 and net loss was $40.9 million. Trailing free cash flow was -$71.7 million, a -50.5% FCF yield against a $142.1 million market cap. ROE and ROCE are deeply negative. The company's Lynch category is none, because it lost money each of the last four years. The business is two things: a digital asset treasury tied to Solana and a neurological device. Neither has produced consistent earnings. A digital asset treasury depends on token prices, capital markets access, and dilution; the medical device may need years and regulatory spending. I see no durable moat in the numbers—only a small 21-employee operation with volatile asset exposure. At the 2026-10-13 close of $2.35, FairStock calculates P/B 0.84, P/E 0.04, Graham Number $58.29, and margin of safety 95.97%, but those ratios sit atop negative earnings and cash burn, so I distrust them as value signals. The Altman Z-Score 10.70 and Piotroski 4/9 are mixed. Price is far below the 52-week high of $15.80, but cheapness without earning power is often a trap. I would want evidence of positive cash flow and real, repeatable revenue before calling this a bargain.

In plain English: Solana Company is a small public company that owns Solana tokens and also develops a medical device for balance and gait problems. It is losing a lot of money: in the quarter ended June 30, 2026, it earned $2.5 million in revenue but lost $30.3 million. The stock price has fallen sharply and some calculated value measures look cheap, but the business itself looks weak and unproven.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer